Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group (Q57571575)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 January 2000

Language	Label	Description	Also known as
English	Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group	scientific article published on 01 January 2000

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741296%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741296%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741296%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741296%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

author name string

O S Nielsen

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741296%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

I Judson

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741296%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Q van Hoesel

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741296%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

A le Cesne

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741296%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

H J Keizer

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741296%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

A van Oosterom

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741296%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

L Svancárová

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741296%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

K Krzemienlecki

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741296%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

C Hermans

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741296%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

M van Glabbeke

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741296%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

J W Oosterhuis

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741296%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

J Verweij

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741296%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

publication date

1 January 2000

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741296%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741296%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

36

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741296%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741296%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

61-67

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741296%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

The management of adult soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in soft tissue sarcomas: the Aarhus experience

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of adjuvant chemotherapy in the treatment of adult soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxorubicin in relapsed soft tissue sarcoma: justification of phase II evaluation of new drugs in this disease. An EORTC Soft Tissue and Bone Sarcoma Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Synovial sarcoma. Uniform response of metastases to high dose ifosfamide

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality control of validity of data collected in clinical trials. EORTC Study Group on Data Management (SGDM).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The importance of dose intensity in chemotherapy of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose ifosfamide with mesna uroprotection: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose ifosfamide is associated with severe, reversible cardiac dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(99)00240-3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741296%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741296%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57571575&oldid=2229928642"